Navigation Links
Astellas in Medical News

Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)

SAN DIEGO and DEERFIELD, Ill., August 3 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company and Astellas Pharma US, Inc. ("Astellas"), announced today their exclusive co-promotion agreement for Sumavel DosePro (sumatriptan injection) needle-free delive...

AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners

The American Urological Association (AUA) Foundation has announced its Astellas Rising Stars in Urology for 2009. William Roberts, MD, of the University of Michigan, and Edward Schaeffer, MD, of Johns Hopkins Medicine are this year's recipients of the award, one of the most prestigious research aw...

NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)

Conference Call Today at 9:00am ET Covers Europe, Middle East and Africa Includes Licensing Option and Development Funding for NGX-1998 SAN MATEO, Calif. and STAINES, England, June 22 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ) and Astellas Pharma ...

Cardiome And Astellas Announce Regulatory Update

NASDAQ: CRME TSX: COM VANCOUVER and DEERFIELD, IL, Jan. 21 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") today announced that they have been informed by the U.S. Food and Dr...

Five Questions About Eczema

...ent full Prescribing Information, Deerfield, Ill., astellas Pharma US, Inc. 2006 25. Protopic(R) (tacrolimu...ent full Prescribing Information, Deerfield, Ill., astellas Pharma US, Inc. 2006 26. Protopic(R) (tacrolimu...ent full Prescribing Information, Deerfield, Ill., astellas Pharma US, Inc. 2006 ...

Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

...strophe (a non-apoptotic pathway). Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from astellas Deutschland GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corpora...

Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms

...ia. Tamsulosin, the most widely-used alpha blocker for the indication, is marketed by Boehringer Ingelheim as Flomax/Josir/Alna/Pradif/Urolosin and by astellas as Omix/Omnic/Flomaxtra/Harnal. Generic versions of tamsulosin have been available in Europe and Japan since 2006 and, in the first half of 2010, the ...

NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors

...pportune time to resign, I feel confident that NeurogesX is well positioned following the recent E.U. approval of Qutenza(TM) and the partnership with astellas Pharma Europe Ltd. to commercialize Qutenza in Europe, and for the ongoing NDA review in the United States. In the wake of these accomplishments I am ...

Astellas Names Head of Global R&D Operations

... DEERFIELD, Ill., June 10 /PRNewswire/ -- astellas Pharma Global Development ("APGD"), a subsidiary of astellas Pharma Inc. based in Tokyo, Japan, announced today...ations. "We are pleased that Peter has joined astellas and we know that he will contribute significantly ...

Astellas Adds CNS Therapy Area Leader to Global R&D Team

... DEERFIELD, Ill., June 4 /PRNewswire/ -- astellas Pharma Global Development ("APGD"), a subsidiary of astellas Pharma Inc. based in Tokyo, Japan, announced today...irection and leadership for the development of all astellas CNS compounds," said Dr. Steven Ryder, president o...
Astellas in Medical Technology

Cardiome And Astellas Announce Positive Results From ACT 2 Trial

NASDAQ: CRME TSX: COM VANCOUVER and DEERFIELD, IL, June 04, 2007 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") today announced results from their recently completed Phase 3 clinical study, called ACT 2. The trial evaluated the e...

Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity

...al infections." Calixa Therapeutics acquired the global development rights (exclude certain Asia-Pacific territories) to CXA-101 (FR264205) from astellas Pharma Inc. in 2007. CXA-101's potent in vitro activity against Pseudomonas aeruginosa has the potential to address the unmet medical need pose...

Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma

...m of action of TREANDA remains unknown. Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from astellas Pharma GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corporation L...

Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm

...itish Columbia, March 25 /PRNewswire-FirstCall/ -- astellas Pharma US, Inc. and its co-development partner Car... Duke University Medical Center and consultant for astellas Pharma US. About ACT I The Phase III study, re...tion, diabetes and sleep apnea. About Astellas astellas Pharma US, Inc., located in Deerfield, Illinois, i...

GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program

...the six programs in development, four are in late stage -- its telavancin program focusing on treating serious Gram-positive bacterial infections with astellas Pharma Inc., the Gastrointestinal Motility Dysfunction program, the Horizon program (Beyond Advair collaboration) with GlaxoSmithKline, and TD-1792 fo...

TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

...ission are also being presented at ASH. Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from astellas Pharma GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corporation L...

TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil

... or following treatment with rituximab. Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from astellas Pharma GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corporation L...

Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery

... ORLANDO, Fla., Nov. 7 /PRNewswire/ -- astellas Pharma US, Inc. today announced that the investiga... inflammation, diabetes and sleep apnea(2). About astellas astellas Pharma US, Inc., located in Deerfield, Illinois, i...

Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia

... DEERFIELD, Ill., Oct. 25 /PRNewswire/ -- astellas Pharma US, Inc. today announced data demonstrating...(1,2) About VAPRISOL Discovered and developed by astellas Pharma Inc. headquartered in Tokyo, Japan, VAPRISO...n be accessed at http://www.VAPRISOL.com . About astellas ...

Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma

...ributable to its unique chemical design. Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from astellas Deutschland GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corporat...
Astellas in Biological News

Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc.

... and the company now stands to reap $537 million through an acquisition by astellas Pharma Inc., making it one of the largest Los Angeles-based private biotech...uct development. According to Belldegrun, the acquisition of Agensys by astellas Pharma is a promising example of what can be done when entrepreneurial effo...
Astellas in Biological Technology

CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal

PALO ALTO, Calif., Feb. 20 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) today announced that its board of directors has thoroughly reviewed and rejected the previously announced unsolicited proposal from Astellas Pharma Inc. to acquire CV Therapeutics at a price of $16.00 per ...

CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection

-First A2A Adenosine Receptor Agonist Approved for Use as Pharmacologic Stress Agent in Myocardial Perfusion Imaging- PALO ALTO, Calif. and DEERFIELD, Ill., April 10 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) and Astellas Pharma US, Inc. today announced that t...

CV Therapeutics Statement on Unsolicited Proposal From Astellas

PALO ALTO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- In light of an announcement made recently by Astellas Pharma Inc., CV Therapeutics, Inc. (Nasdaq: CVTX ) confirmed that it had received a letter dated November 13, 2008 from Astellas setting forth an unsolicited proposal by Astellas to acquire...

NeurogesX Reports Second Quarter 2009 Results

...ts for pain Entered exclusive agreement with astellas Pharma Europe Ltd. (Astellas) for commercializatio...l, NeurogesX finalized an exclusive agreement with astellas Pharma Europe Ltd. (Astellas) for the commercializ...cial company while finalizing our partnership with astellas fulfilled an important part of our global commerci...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

...r medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) whic...

Five Questions About Protopic (tacrolimus) Ointment

...pic(R) (tacrolimus) Ointment full Prescribing Information, Deerfield, Ill., astellas Pharma US, Inc. 2006 Protopic(R) (tacrolimus) Ointment full Prescribing Information, Deerfield, Ill., astellas Pharma US, Inc. 2006 Protopic Ointment full Prescribing Information, ...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

...ion and certain countries in Eastern Europe, the Middle East and Africa, by astellas Pharma Europe Ltd., a subsidiary of astellas Pharma Inc. In the United States, NeurogesX submitted a new drug applicatio...

R-Tech Ueno Notifies R&D Items

...for the indication of atrophic age-related macular degeneration. 2. Development code RTU-007 (eye diseases) The license is obtained from astellas Pharma Inc. for the substance to inhibit the enzyme that increases in patients with diabetes mellitus. We intend to proceed with the development of th...

SynCo Bio Partners Increases its Capacities by Expanding its Quality Team

...s, with the addition of a second Qualified Person (QP) to its Quality Affairs team: Raoul Fisser Raoul joined SynCo's Quality Affairs team from astellas Pharma where he worked in Pharmaceutical Development, having previously gained experience in the Quality Assurance Department of the largest manufactu...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...Probe Introduces Innovative Test for Prostate Cancer in Europe II-85 DRL Introduces Generic Version of Proscar II-85 Ferring Partners with astellas on Degarelix License for Prostate Cancer Treatment II-85 Protox Acquires PRX321 Cancer Program from US Public Health Service and Neurocrin...
Other Tags
(Date:7/11/2014)... 11, 2014 The International Concussion ... at the Best Buy Theater in Times Square, ... to the growing concussion epidemic that is plaguing ... levels of competition. , The Symposium gathers more ... researchers, coaches, professional athletes and legal scholars for ...
(Date:7/11/2014)... Newport Beach, CA (PRWEB) July 11, 2014 ... product pure Artichoke Leaf Extract dietary supplements to aid ... flow, an action necessary to facilitate metabolism of fat. ... facilities, Superior Labs Artichoke Leaf Extract is available in ... of pure artichoke extract. , Health Benefits of ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... begin this August in New York. ... cover: , -Myofascial Trigger Point Therapy, ... -Mobilization & Thrust Manipulation, -Neuroobilization & Neurodynamics, ... prescribing to a single, isolated manual therapy ...
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Plasma ... of blood products industry. Although the closure of 16 ... major disruption to domestic blood products market, the total ... 2.8% year on year and total lot release volume ... due to stock consumption, insufficient utilization of new plasma ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 This morning(July 9th, ... 13--Good Morning Memphis to discuss the illegal immigration crisis at ... town of McAllen, Texas. , Dr. Flinn told Good Morning ... is absolutely wide open… The problem is that they do ... Thousands of people per day are coming into the border; ...
Breaking Medicine News(10 mins):Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2Health News:Artichoke Leaf Extract Released by SuperiorLabs Now Available on Amazon.com With 2 Day Prime Shipping 2Health News:Artichoke Leaf Extract Released by SuperiorLabs Now Available on Amazon.com With 2 Day Prime Shipping 3Health News:Hands-On Seminars, the Leader in Manual Therapy Continuing Education, Announces Series of Comprehensive Hands-On Training Courses 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 3Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 4Health News:Senate Candidate, George Flinn on Fox13 NEWS About the Border Crisis 2
(Date:7/10/2014)... 2014 Fingerprint Cards, (FPC,s) new mobile ... (DW). A Chinese Top 5 smartphone OEM has selected FPC1021 ... production in October 2014.   FPC is proud ... OEM, which has a planned date for the start of ... for this phone of 3 million units. The Chinese OEM ...
(Date:7/10/2014)... , July 9, 2014  Acuity Market Intelligence today ... Report: 2014 Edition" indicating that the global market for National ... between 2013 to 2018. During this time, the number of ... to 3.5 billion. Asia , with its ... all National eID cards issued, while Europe ...
(Date:7/10/2014)... main organization of the International Science and Business Belt ... of researchers, led by professor Won Do Heo, have ... that can remotely control specific receptors by light. They ... succeeded with neuronal differentiation inducement. , The most significant ... light to activate neuronal functions without the need of ...
Breaking Biology News(10 mins):FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2New optogenetic tool for controlling neuronal signalling by blue light 2
Other Contents